Naproksen a bezpieczeństwo kardiologiczne podczas stosowania niesteroidowych leków przeciwzapalnych Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2020
Słowa kluczowe:
niesteroidowe leki przeciwzapalne, naproksen, powikłania sercowo-naczyniowe
##plugins.themes.bootstrap3.article.main##
Abstrakt
Niesteroidowe leki przeciwzapalne (NLPZ) są szeroko stosowane na świecie w leczeniu bólu i chorób zapalnych. W ostatnich latach powszechne użycie doustnych NLPZ zostało zakwestionowane z powodu pojawiania się powikłań ze strony przewodu pokarmowego i układu sercowo-naczyniowego. NLPZ są niejednorodną grupą leków znacznie różniących się pod względem mechanizmu działania oraz ryzyka działań niepożądanych na przewód pokarmowy i układ sercowo-naczyniowy. Niektóre z nieselektywnych NLPZ zostały wycofane z rynku pomimo wysokiego bezpieczeństwa gastroenterologicznego, ponieważ niekorzystnie wpływały na układ krążenia. Zaowocowało to licznymi badaniami nad bezpieczeństwem sercowo-naczyniowym innych NLPZ. W wielu próbach stwierdzono, że naproksen i celekoksyb są bezpieczne w porównaniu z ibuprofenem i diklofenakiem u pacjentów ze zwiększonym ryzykiem sercowo-naczyniowym. Wykazano również, że jednoczesne stosowanie naproksenu z kwasem acetylosalicylowym utrzymuje jego kardioprotekcyjne działanie. Właściwe leczenie NLPZ powinno być poprzedzone staranną oceną kliniczną pacjentów i wyborem odpowiedniego NLPZ.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Lewandowski , J. (2020). Naproksen a bezpieczeństwo kardiologiczne podczas stosowania niesteroidowych leków przeciwzapalnych . Medycyna Faktów , 13(2(47), 180-187. https://doi.org/10.24292/01.MF.0220.6
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther. 2000; 7(2): 115-21.
2. Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int. 2012; 32(6): 1491-502.
3. Jones R. Nonsteroidal anti-inflammatory drug prescribing: past, present, and future. Am J Med. 2001; 110(1A): 4S-7S.
4. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971; 231(25): 232-5.
5. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. 1998; 104(3A): 2S-8S; discussion 21S-2S.
6. Snowden S, Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol Rev. 2011; 19(4): 184-91.
7. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001; 286(8): 954-9.
8. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343(21): 1520-8, 2 p following 8.
9. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000; 284(10): 1247-55.
10. Johnson AG. NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf. 1997; 17(5): 277-89.
11. Ruschitzka F, Borer JS, Krum H et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION- ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J. 2017; 38(44): 3282-92.
12. Sowers JR, White WB, Pitt B et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005; 165(2): 161-8.
13. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994; 121(4): 289-300.
14. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332(7553): 1302-8.
15. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med. 2002; 162(10): 1111-5.
16. Watson DJ, Rhodes T, Cai B et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002; 162(10): 1105-10.
17. Schjerning Olsen AM, Fosbol EL, Lindhardsen J et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011; 123(20): 2226-35.
18. Olsen AM, Fosbol EL, Lindhardsen J et al. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients--a nationwide study. PLoS One. 2013; 8(1): e54309.
19. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011; 8(9): e1001098.
20. Fosbol EL, Gislason GH, Jacobsen S et al. Risk of myocardial infarction and death associated with the use of nonsteroidal antiinflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009; 85(2): 190-7.
21. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382(9894): 769-79.
22. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989; 321(3): 129-35.
23. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329): 71-86.
24. Li X, Fries S, Li R et al. Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA. 2014; 111(47): 16830-5.
25. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001; 345(25): 1809-17.
26. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003; 361(9357): 573-4.
27. Hohlfeld T, Saxena A, Schror K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs – pharmacological mechanisms and clinical relevance. Thromb Haemost. 2013; 109(5): 825-33.
28. Alqahtani Z, Jamali F. Clinical Outcomes of Aspirin Interaction with Other Non-Steroidal Anti-Inflammatory Drugs: A Systematic Review. J Pharm Pharm Sci. 2018; 21(1s): 29854.
29. Capone ML, Tacconelli S, Sciulli MG et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004; 109(12): 1468-71.
30. Kurth T, Glynn RJ, Walker AM et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation. 2003; 108(10): 1191-5.
31. Burmester G, Lanas A, Biasucci L et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011; 70(5): 818-22.
32. Scarpignato C, Lanas A, Blandizzi C et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015; 13: 55.
33. Samborski W, Filipiak KJ, Kaczmarczyk J et al. Niesteroidowe leki przeciwzapalne a powikłania sercowo-naczyniowe i gastroenterologiczne – algorytm wyboru. Choroby Serca i Naczyń. 2016; 13(4): 257-64.
34. Piepoli MF, Hoes AW, Agewall S et al. [2016 European Guidelines on cardiovascular disease prevention in clinical practice]. Kardiol Pol. 2016; 74(9): 821-936.
35. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011; 342: c7086. https://doi.org/10.1136/bmj.c7086.
2. Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int. 2012; 32(6): 1491-502.
3. Jones R. Nonsteroidal anti-inflammatory drug prescribing: past, present, and future. Am J Med. 2001; 110(1A): 4S-7S.
4. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971; 231(25): 232-5.
5. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. 1998; 104(3A): 2S-8S; discussion 21S-2S.
6. Snowden S, Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol Rev. 2011; 19(4): 184-91.
7. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001; 286(8): 954-9.
8. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343(21): 1520-8, 2 p following 8.
9. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000; 284(10): 1247-55.
10. Johnson AG. NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf. 1997; 17(5): 277-89.
11. Ruschitzka F, Borer JS, Krum H et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION- ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J. 2017; 38(44): 3282-92.
12. Sowers JR, White WB, Pitt B et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005; 165(2): 161-8.
13. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994; 121(4): 289-300.
14. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332(7553): 1302-8.
15. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med. 2002; 162(10): 1111-5.
16. Watson DJ, Rhodes T, Cai B et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002; 162(10): 1105-10.
17. Schjerning Olsen AM, Fosbol EL, Lindhardsen J et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011; 123(20): 2226-35.
18. Olsen AM, Fosbol EL, Lindhardsen J et al. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients--a nationwide study. PLoS One. 2013; 8(1): e54309.
19. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011; 8(9): e1001098.
20. Fosbol EL, Gislason GH, Jacobsen S et al. Risk of myocardial infarction and death associated with the use of nonsteroidal antiinflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009; 85(2): 190-7.
21. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382(9894): 769-79.
22. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989; 321(3): 129-35.
23. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329): 71-86.
24. Li X, Fries S, Li R et al. Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA. 2014; 111(47): 16830-5.
25. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001; 345(25): 1809-17.
26. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003; 361(9357): 573-4.
27. Hohlfeld T, Saxena A, Schror K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs – pharmacological mechanisms and clinical relevance. Thromb Haemost. 2013; 109(5): 825-33.
28. Alqahtani Z, Jamali F. Clinical Outcomes of Aspirin Interaction with Other Non-Steroidal Anti-Inflammatory Drugs: A Systematic Review. J Pharm Pharm Sci. 2018; 21(1s): 29854.
29. Capone ML, Tacconelli S, Sciulli MG et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004; 109(12): 1468-71.
30. Kurth T, Glynn RJ, Walker AM et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation. 2003; 108(10): 1191-5.
31. Burmester G, Lanas A, Biasucci L et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011; 70(5): 818-22.
32. Scarpignato C, Lanas A, Blandizzi C et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015; 13: 55.
33. Samborski W, Filipiak KJ, Kaczmarczyk J et al. Niesteroidowe leki przeciwzapalne a powikłania sercowo-naczyniowe i gastroenterologiczne – algorytm wyboru. Choroby Serca i Naczyń. 2016; 13(4): 257-64.
34. Piepoli MF, Hoes AW, Agewall S et al. [2016 European Guidelines on cardiovascular disease prevention in clinical practice]. Kardiol Pol. 2016; 74(9): 821-936.
35. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011; 342: c7086. https://doi.org/10.1136/bmj.c7086.